Effect of PTX3 and voriconazole combination in a rat model of invasive pulmonary aspergillosis.

Abstract

This study evaluated the pharmacological activity of PTX3, administered in combination with voriconazole, in a rat model of pulmonary aspergillosis. The data indicated additive therapeutic activities of these compounds, as demonstrated by the amelioration of respiratory function changes, reduction of lung fungal burden, and increased survival. Overall, we provide clear evidence that the combination of PTX3 with a suboptimal dose of voriconazole might represent a therapeutic option under those clinical conditions where the use of voriconazole alone is not warranted for efficacy and tolerability reasons.

• Authors: Pietro Lo Giudice, Silvia Campo, Rita De Santis, Giovanni Salvatori
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 56 Issue 12 Pg. 6400-2 (Dec 2012) ISSN: 1098-6596 [Electronic] United States
• PMID: 23006752 (Publication Type: Journal Article)

Chemical References

• Antifungal Agents
• Drug Combinations
• Immunosuppressive Agents
• Mannans
• Pyrimidines
• Serum Amyloid P-Component
• Triazoles
• galactomannan
• PTX3 protein
• C-Reactive Protein
• Voriconazole
• Cortisone
• Galactose

Topics

• Animals
• Antifungal Agents (therapeutic use)
• Body Burden
• C-Reactive Protein (therapeutic use)
• Colony Count, Microbial
• Cortisone (pharmacology)
• Drug Combinations
• Galactose (analogs & derivatives)
• Immunosuppressive Agents (pharmacology)
• Kaplan-Meier Estimate
• Lung (microbiology)
• Mannans (metabolism)
• Organ Size
• Pulmonary Aspergillosis (drug therapy, microbiology)
• Pyrimidines (therapeutic use)
• Rats
• Respiratory Function Tests
• Serum Amyloid P-Component (therapeutic use)
• Survival
• Triazoles (therapeutic use)
• Voriconazole